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Designing hybrid proteins is a major aspect of protein engineering and covers a very wide range of applications from basic research
to medical applications. This review focuses on the use of class A 𝛽-lactamases as versatile scaffolds to design hybrid enzymes
(referred to as 𝛽-lactamase hybrid proteins, BHPs) in which an exogenous peptide, protein or fragment thereof is inserted at
various permissive positions. We discuss how BHPs can be specifically designed to create bifunctional proteins, to produce and to
characterize proteins that are otherwise difficult to express, to determine the epitope of specific antibodies, to generate antibodies
against nonimmunogenic epitopes, and to better understand the structure/function relationship of proteins.
1. Introduction
Engineering proteins with improved properties or new
functions is an important goal in biotechnology. In this
context, numerous bi- or multifunctional proteins have been
created for applications in a broad range of fields including
biochemical analysis, protein purification, immunodetection,
protein therapies, vaccine development, functional genomics,
analysis of protein trafficking and analysis of protein interac-
tion network [1]. The most common strategy to create such
proteins involves fusing polypeptides into an end-to-end con-
figuration. For example, the fusion of proteins with specific
tagging domains is nowadays a standard tool for protein
engineering. Indeed, numerous commercial kits allow the
fusion of a protein of interest to an affinity polypeptide such
as 6-Histidine tag, maltose-binding protein, and glutathione
transferase [1]. Moreover, the fusion of a protein of interest
to the green fluorescent protein (GFP) has become one of the
most important tools used in contemporary bioscience, and
O. Shimomura, M. Chalfie, and R. Y. Tsien were rewarded
the Chemistry Nobel prize in 2008 for the initial discovery of
GFP and development of important GFP-based applications.
Another strategy to create hybrid proteins, although
much less commonly used, is to insert (or graft) a pep-
tide/protein/fragment thereof at a permissive site of a carrier
protein. For example, Collinet et al. [2] have successfully
created bi- or trifunctional hybrid enzymes by inserting
the dihydrofolate reductase (159 aa) and/or the TEM-1 𝛽-
lactamase (263 aa) into four different positions of phospho-
glycerate kinase (415 aa). Betton et al. [3] have created hybrid
proteins by inserting the TEM-1 𝛽-lactamase at various sites
into theMalEmaltodextrin-binding protein, that is, positions
120, 133, and 303, or by fusing it to the carboxy terminus
of MalE. Insertion at positions 133 and 303 or fusion at
the C-terminus allows the production in the periplasm of
hybrid proteins exhibiting both parental activities; indeed,
the maltose binding and the penicillinase activity of these
hybrid proteins is indistinguishable from that of, respectively,
MalE and TEM-1 [3]. Interestingly, the two proteins with
insertions displayed two additional properties compared to
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their C-terminal fusion counterpart: (i) they were more
resistant to degradation by endogenous proteases and, (ii)
even more remarkably, the TEM-1 moiety was stabilized
against urea denaturation through the binding to MalE of
maltose, that is, its natural ligand. This latter observation
clearly demonstrates that TEM-1 is structurally dependent
on MalE or in other words that an allosteric interaction
occurs between the two proteins [1, 3]. Thus, insertion of
a polypeptide inside a scaffold protein can present some
advantages compared to the more common end-to-end
fusion. This strategy actually mimics that used by nature to
generate protein diversity. Indeed, genetic rearrangements,
such as the introduction of a sequence into an unrelated
coding sequence, naturally occur in the genome [2]. The
resulting proteins are composed of two or more domains,
and the linear sequence of one domain is interrupted by the
insertion, forming discontinuous domains. This process has
been shown for large natural proteins such as disulfide bond
isomerase A (dsbA) [4], DNA polymerase [5], and pyruvate
kinase [6]. A systematic survey of structural domains showed
that ∼28% of them are actually not continuous, clearly
indicating that the sequence continuity of a domain is not
required for correct folding and function [2, 7].
In this review, we report the use of two class A 𝛽-lactam-
ases to create hybrid proteins (𝛽-lactamase hybrid proteins,
BHPs) in which exogenous peptides/proteins/fragments
thereof are inserted within 𝛽-lactamase sequences. Such
hybrid proteins can be designed for a range of applications
such as (i) the creation of bifunctional hybrid proteins [8–
11], (ii) the production, purification, and characterization of
proteins otherwise difficult to express [10, 12, 13], (iii) the
determination of the epitope of a specific antibody at the
surface of an antigen [8, 11], (iv) the generation of antibodies
against specific antigens or fragments thereof [9, 13–15], and
(v) the investigation of fundamental aspects of structure,
stability, and function of proteins [10, 12, 16].
2. Class A 𝛽-Lactamases as Scaffolds to
Create Hybrid Enzymes
2.1. Why the Use of Class A 𝛽-Lactamases? The two class
A 𝛽-lactamases that have been extensively used as model
proteins to insert exogenous polypeptides are BlaP from
Bacillus licheniformis 749/C and TEM-1, the latter being the
most encountered 𝛽-lactamase in gram-negative bacteria
(Figure 1). These two enzymes are, respectively, secreted
by bacteria in the external environment and expressed in
the periplasmic space to inactivate 𝛽-lactam antibiotics.
About 40% and 20% of the amino acids are, respectively,
identical and homologous between these two serine-active
𝛽-lactamases (Figure 1). Note that the residue numbering
used in this review is that specific to class A 𝛽-lactamases
[17].These enzymes, especially TEM-1, have been extensively
used as reporters to study gene expression [21–23] and for
immunoassays [24]. They have been selected as scaffolds
to create hybrid proteins based on a series of observations.
Firstly, they are fairly small (30 kDa) and stable proteins
that are easily overexpressed in E. coli and subsequently
purified [9–11]. Their three-dimensional structure has been
determined by X-ray crystallography (Figure 1) [18, 19, 25,
26].They exhibit the typical class A 𝛽-lactamase 3D structure
which is composed of two domains: an 𝛼/𝛽 domain and an
all-𝛼 domain, with the catalytic site at the interface between
the two domains [19, 25, 26]. Finally, their catalytic prop-
erties have been thoroughly characterized and can be easily
monitored using fluorescent [22, 23, 27] or chromogenic
substrates [28]. This latter point is crucial as exemplified in
the following sections. The enzymatic activity of the BHPs
serves as a reporter to select clones resistant to 𝛽-lactam
antibiotics, such as ampicillin, expressing well-folded and
active BHP. It is assumed that the folding of the exogenous
polypeptide and the carrier enzyme are interdependent to
some degree. Indeed, the correct folding of the carrier 𝛽-
lactamase requires the exogenous polypeptide to be exposed
to the solvent; otherwise, the 𝛽-lactamase cannot adopt
its native structure. Moreover, the correct folding of the
carrier protein imposes constraints at the N- and C-terminal
extremities of the inserted polypeptide, maintaining its two
extremities in close proximity of the insertion site. These
constraints limit therefore the conformational flexibility of
the insert and could assist the insert in adopting its native
structure.When a greater flexibility is required for the correct
folding of the insert, small peptides, that is, linkers, can
be added at both of its extremities. Note that, in some
applications, these linkers have an additional functionality
allowing the excision of the insert thereafter, as discussed in
detail below.
2.2. A Brief History of Class A 𝛽-Lactamase Hybrid Proteins.
The design of class A hybrid 𝛽-lactamases was initiated with
the work of Hallet et al. in 1997 [20]. A random pentapeptide
cassette was inserted at 23 different positions of TEM-1 using
pentapeptide-scanning mutagenesis (Figure 1(a)) [20]. This
method consists of transposing the transposon Tn4430 into
the TEM-1 gene which duplicates 5 base pairs (bp) of host
sequence at the insertion point. This transposon contains
KpnI restriction enzyme sites 5 bp from the outer ends of its
terminal inverted repeats. Digestion with KpnI followed by
ligation results therefore in the insertion of 10 pbderived from
Tn4430 and 5 bp from the 5-nucleotide duplication of the
target gene. Each transposition event leads to a 15 bp insertion
into the TEM-1 gene encoding for a random pentapeptide
cassette. The 23 insertion sites have been classified into 3
groups depending on the level of resistance that the hybrid
protein confers to E. coli cells against ampicillin, a 𝛽-lactam
antibiotic (Figure 1(a)): (i) 5 permissive sites (197, 198, 265,
270, and 272) with high level of resistance. These sites are
located into two loops distant from the catalytic site, one loop
between 𝛼 helices 8 and 9 and the other between 𝛽-strand 5
and the C-terminal helix. (ii) Eight non-permissive sites (63,
68, 163, 164, 208, 232, 233 and 246) associated with the loss
of the 𝛽-lactamase activity and clustered around the catalytic
site. (iii) Ten semi-permissive sites (37, 97, 99, 119, 206, 216,
218, 260, 264, and 276) are conferring an intermediate level
of ampicillin resistance.
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Figure 1: X-ray crystal structure and sequence of TEM-1 (a) and BlaP (b). The residue numbering is based on homology to class A 𝛽-
lactamases [17]. The structures were produced using PyMOL (DeLano Scientific LLC, South San Francisco, CA, USA) and the PDB ID is
4BLM for BlaP [18] and 1XPB for TEM-1 [19]. (a) TEM-1. The residues of the active site are represented in green on the structure and are
coloured and underlined in the sequence. The different insertion sites of pentapeptides reported in Hallet et al. [20] are coloured on the
structure and are coloured and underlined in the sequence. Light blue, orange and red are associated with permissive, semi-permissive, and
non-permissive insertion sites, respectively. (b) BlaP from Bacillus licheniformis 749/C.The residues of the active site are represented in green
on the structure, and are coloured and underlined in the sequence.The two insertion sitesmost commonly used to design BHPs, located in the
loop between 𝛼 helices 8 and 9 (197-198) and in the loop between 𝛼 helices 9 and 10 (216-217), are indicated in light blue on the structure and
are coloured and underlined in the sequence. The PG dipeptide between residues 197 and 198 indicated in bold in the sequence corresponds
to the SmaI restriction site inserted into the gene of BlaP for the cloning of exogenous polypeptides at this position.
Later, Ruth et al. [9] have inserted longer and more
structured polypeptides in eight of the TEM-1 positions
investigated by pentapeptide-scanningmutagenesis (Table 1).
The thermostable 18-residues STa enterotoxin from entero-
toxic Escherichia coli has been introduced, for example, into
one of the two permissive loops (at position 195 and 198,
between 𝛼 helices 8 and 9), in five semi-permissive sites
(37, 206, 216, 218 and 260) and into one non-permissive site
(232). Insertions between 𝛼 helices 8 and 9 (positions 195–
200) and between 𝛼 helices 9 and 10 (positions 213–220)
allow the production of a soluble hybrid proteinwhich retains
both activities of parental proteins (i.e., ampicillin resistance
and enterotoxicity). The level of activities and the amount
of soluble hybrid enzymes produced depend however on the
position of insertion.
TEM-1 is a 𝛽-lactamase sensitive to many proteases [11,
29]. Some BHPs that do not confer resistance to ampicillin
to E. coli (i.e., BHPs containing insertions at sites identified
as non-permissive) could however be successfully expressed
in protease-deficient E. coli strains.This observation suggests
that insertions at these positions into TEM-1 actually increase
its sensitivity to proteolysis [11]. This increased susceptibility
to proteolysis could be due to local conformational changes
or to a destabilisation of the enzyme upon the insertion
of the exogenous polypeptide. In contrast, BlaP presents
an advantage over TEM-1 in being much less sensitive to
proteases. Indeed, this enzyme evolved to withstand high
levels of various and numerous proteases, which are secreted
by the gram-positive Bacillus licheniformis bacterium [11, 30].
Based on this observation, it was anticipated that BlaP could
constitute an alternative scaffold to TEM-1 to generate hybrid
proteins. Since, as mentioned above, BlaP and TEM-1 share
a high sequence identity and a similar three-dimensional
structure, the permissive sites described for TEM-1 served as
a basis to engineer hybrid BlaP proteins with the insertion of
heterologous polypeptides (Figure 1(b)) [11].
2.3. How Were BHPs Designed? TEM-1 hybrid proteins were
produced in the periplasm of E. coli via pFHX plasmids
derived from the pBR332 plasmid, the X corresponding
to the position of insertion into TEM-1. These plasmids
carry a KpnI restriction site at the position of insertion
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Table 1: Properties of the different BHPs discussed in this review.
Hybrid proteins
[ref]
Insert Effect on stability
(ΔΔG∘H2O—kJ⋅mol
−1)
Effects on the 𝛽-lactamase










Insertion at positions 37,
198, and 206: ND
Insertion at position 195: no
loss of activity
Insertion at positions 197,






9 AA 197 ND No loss of activity







72 AA 197 ∼3.2
No loss or partial loss of





= 5.4 ± 0.5 L g−1




202 AA 197 ND
Activity detected but not
quantified
Binding to mab 8015:
𝐾
𝐷






197 ∼7.6–8.8 No loss of activity
PolyQ tracts longer than a
threshold trigger the
aggregation of BHPs into
amyloid fibrils
The name of the BHPs, the name of the insert, its size, and function are indicated. The effects of the insertion on the stability and on the enzymatic activity of
the 𝛽-lactamase are also reported. ND: not determined.
allowing the insertion of the exogenous sequence.They allow
a constitutive expression of the BHPs which are purified by
ion-exchange chromatography [9].
Most BlaP hybrid proteins, on the other hand, have so
far been created by inserting the exogenous polypeptide at
position 197 within the permissive loop located between the
𝛼 helices 8 and 9 (Figure 1(b)) [10]. A constitutive expression
vector in E. coli (pNYBlaP), which allows the insertion of
heterologous polypeptide sequences into the SmaI restriction
site at position 197 (Figure 1(b)), has been developed [10, 11].
This vector allows the expression, in the periplasm of E. coli,
of the BHP in fusion with a C-terminal His-tag to facilitate
their purification using affinity chromatography.
3. BHPs as Tools to Produce and Study
Difficult to Express Peptides/Proteins
Some proteins are difficult to produce recombinantly because
of their intrinsic properties such as relative insolubility,
instability and/or large size. One strategy to study their
properties (i.e., structure, function, . . .) consists of inserting
these proteins or their structural subdomains into a carrier
protein.
Vandevenne et al. [10] have, for example, designed,
produced, and characterized a hybrid protein in which the
chitin binding domain (ChBD) of the human macrophage
chitotriosidase has been inserted in BlaP at position 197; this
hybrid protein is referred to as BlaP-ChBD (Table 1). The
study of the chitin binding domain of this chitinase is of
interest since (i) the physiological function of mammalian
chitinases remains unknown [31] and, more importantly, (ii)
the concentration of chitotriosidase, a chitinase expressed in
lipid-laden macrophages, is highly elevated in Gaucher dis-
ease [31–33]. Some evidence suggests that mammalian chiti-
nases confer a defensive function against chitin-containing
pathogens, such as fungals, which have cell walls consisting
mainly of chitin; indeed, high levels of chitinases are present
in the serum and tissues of guinea pigs after infection by
Aspergillus fumigates [31, 34, 35]. It is also proposed that the
enzyme could modulate the extracellular matrix in the vessel
wall affecting the downstream tissue-remodelling processes,
associated with atherogenesis.This hypothesis is based on the
fact that macrophages expressing chitinases are abundant in
atherosclerotic plaques [31, 33].
ChBD is a small domain of 8 kDa composed of 72 amino
acids which binds insoluble chitin. It contains 3 disulfide
bridges that are essential for both its structural stability and its
binding to chitin [10, 13, 31].This protein domain is extremely
difficult to produce, and its three-dimensional structure has
not yet been solved [10, 13, 31].
The BlaP-ChBD hybrid protein has been successfully
produced in the periplasm of E. coli and purified in a two-
step procedure, that is, affinity chromatography via a His-
tag designed at the C-terminus of BlaP, followed by anion-
exchange chromatography. Remarkably, the hybrid protein
exhibits both parental activities (Table 1). The 𝛽-lactamase
moiety hydrolyzes its 𝛽-lactam substrates, in the presence
and/or absence of chitin, and the ChBD domain binds to
insoluble chitin with similar 𝐾
𝑟
value (relative equilibrium
association constant), 5.4 ± 0.5 L g−1, of other carbohydrate-
binding domains [10, 13]. It is important to note that the
bifunctionality of the hybrid protein allowed the 𝐾
𝑟
value
between BlaP-ChBD and insoluble chitin to be easily mea-
sured, using the 𝛽-lactamase activity as a reporter. Moreover,
BioMed Research International 5
the hybrid protein allowed the detection of chitin in fungal
cell walls [24]. The fact that ChBD conserves its binding
properties within BlaP suggests that its N- and C-terminal
extremities are proximal in the three-dimensional structure.
In the presence of reducing agents, BlaP-ChBD still exhibited
𝛽-lactamase activity but failed to bind to chitin, confirming
that the 3 disulfide bridges of ChDB are essential to maintain
its functionality.
The effects of the insertion of ChBD on the thermo-
dynamic stability of BlaP were extensively characterized.
Despite the multidomain character of BlaP-ChBD, urea
unfolding occurs according to a simple two-state mechanism
and is fully reversible [10]. The insertion of ChBD in posi-
tion 197, however, slightly destabilizes BlaP by 3.2 kJ⋅mol−1
(Table 1). Moreover, the thermal unfolding of BlaP-ChBD
was found to be less reversible and less cooperative than
that of BlaP. Indeed, the thermal transition observed for
BlaP-ChBD by differential scanning calorimetry (DSC) and
far UV circular dichroism is characteristic of a three-state
transition while the one observed for BlaP is characteristic
of a two-state transition. This suggests that, within the
hybrid protein, ChBD and BlaP unfold individually upon
temperature increase [10].
The ChBD domain has also been inserted in position
197 of BlaP between two thrombin (Thb) cleavage sites; this
hybrid protein is referred to as BlaP-Thb/CHBD/Thb (Table 1)
[13]. This construction allowed easy separation of the ChBD
domain from the BlaP carrier protein, following the action of
the thrombin and subsequent purification. Upon proteolytic
cleavage, theN- andC-terminal parts of BlaP remain strongly
linked together and are separated from the ChBD domain by
depletion using affinity chromatography via the C-terminal
His-tag (Figure 2). Remarkably, the thrombin cleavage did
not significantly alter either the activity of BlaP or that of
of ChBD (Table 1), and ∼18mg of highly soluble and active
ChBD was obtained per litre of culture [13, 24].
These studies clearly demonstrate that BlaP is an effi-
cient scaffold to create bifunctional enzyme and to produce,
purify, and characterize protein fragments that are otherwise
difficult to express. This approach has been further used
to produce various polypeptides of up to 40 kDa in size
(unpublished results). Moreover, these results show that the
BHPs can be used (i) to easily investigate the biological
function of the polypeptide/protein inserted such as its
interaction with a series of ligands using the 𝛽-lactamase
activity as a reporter, (ii) to screen therapeutic molecules,
that is, molecules neutralizing the biological properties of the
polypeptide inserted, as further exemplified in the section
of this review describing the use of BlaP for vaccine devel-
opment, (iii) to screen molecules stabilizing and preventing
protein aggregation (see section “BHPs as model proteins
to investigate structure/function relationships”), and (iv) to
facilitate the determination of the three-dimensional struc-
ture of polypeptides that are otherwise unnameable to X-ray
crystallography due to their insolubility, since BHPs allow an
increase in the solubility of the insert [10, 12, 13].
4. BHPs: an Original Approach to Map and
Functionalize Epitopes
The determination of the epitope (i.e., the region of the
antigen that is recognized by an antibody or an antibody
fragment, which can be linear or conformational) is of crucial
importance to understand, at the molecular level, the rela-
tionship between the structure and function at the antigen-
antibody interface [8]. For example, the determination of the
epitope recognized by two heavy-chain antibody fragments
specific to human lysozyme has allowed a better understand-
ing of how they prevent in vitro amyloid fibril formation
by the amyloidogenic variants of human lysozyme [36, 37].
Moreover, the identification of the epitope enables the design
and isolation of new antibody analogues, having higher
affinity for their antigen or exhibiting different biological
activities, or smaller antibody mimetics (i.e., peptides and
smallmolecules interactingwith the same epitope region) [8].
Epitopemapping is also essential in diagnostic, immunother-
apy, and vaccine development.
Different techniques have been developed to identify
epitopes. The gold standard for epitope identification is
the determination of the three-dimensional structure of the
antigen-antibody complex by X-ray crystallography. This
technique is, however, not always easy to perform due to
the difficulty of obtaining high concentrations of a good
quality complex and finding the proper conditions of crys-
tallisation [8, 38]. Alternative biophysical techniques include
(i) H/D exchange experiments on the antigen-antibody
complex coupled to proteolysis with pepsin and subsequent
analysis of the digested fragments by mass spectrometry
(deuterium exchange mass spectrometry) [39] and (ii) NMR
spectroscopy by comparing, for example, heteronuclear single
quantum coherence (HSQC) spectra, of small target proteins
in the presence or absence of the antibodies [40]. For all
these structural approaches, high quantities of pure and stable
antigens are however required, and some of them are limited
by the size of the complex [8]. Another set of approaches is
based on the exposition of numerous small peptides (overlap-
ping sequences from the natural antigen or peptide mixtures
derived from a combinatorial library if the antigen sequence
is unknown) on a chip (peptide arrays) [41], or at the surface
of phages (phage display) [42–46]. Phage display is based
on the expression of a peptide/protein/protein fragment of
interest at the surface of phage particles, fused to one of
their coat proteins [42, 47, 48]. The power of this technique
is the physical link between the phenotype (the expression
of the peptide/protein/protein fragment of interest that can
interact with its ligand) and the genotype (the nucleotide
sequence of the peptide/protein/protein fragment cloned
into the phagemid genome) [42, 48]. Phage display allows
high-throughput screening of libraries of variant nucleotide
sequences with diversity up to 106 to 1010 [11, 42, 49].
Innovative phage display strategies are continuously
implemented [50]. One of them is based on the use of the 𝛽-
lactamase hybrid protein to expose random peptides/protein
fragments at the surface of the phages and therefore to
enzymatically functionalize the epitope (Figure 3) [8, 11,










































Figure 2: Schematic representation of the protocol used to cleave the ChBD domain from BlaP and to purify it. Purified ChBD is collected
in the flow through after loading the hybrid protein digested by thrombin on an immobilized metal ion affinity chromatography (IMAC).
Figure adapted fromVandevenne et al., 2008 [13]. BlaP-Cter: C-terminal sequence of BlaP, starting at the insertion site. BlaP-Nter: N-terminal
sequence of BlaP ending at the insertion site.
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Figure 3: BHPs as unique tools for epitope mapping. Schematic representation of the epitope mapping procedure developed by Bannister
et al. and Chevigne´ et al. [8, 11]. The steps for which the enzymatic activity of BlaP, as a reporter or as factor for selection, is critical are
highlighted in red. BlaP-Cter: C-terminal sequence of BlaP, starting at the insertion site. BlaP-Nter: N-terminal sequence of BlaP ending at
the insertion site. Anti-Ag mab: monoclonal antibody specific to the targeted antigen. Following the elution of phages after the last round of
panning, a peptide array can be carried out to verify that the entire antigen sequence is well represented in the phage library. Alanine scanning
mutagenesis can be carried out to determine which residues of the minimal sequence encompassing the epitope is in direct contact with the
antigen. Figure adapted from Chevigne´ et al., 2007 [11].
51]. The advantages of this strategy are numerous [11, 51].
First, the polypeptide exposed within the 𝛽-lactamase could
have a restricted conformational freedom and be somehow
protected from proteolytic cleavage [3]. As illustrated in
Figure 3, the main implementation is, however, associated
with the use of 𝛽-lactamase activity which can be easily
detected with chromogenic substrates such as nitrocefin [11].
The 𝛽-lactamase activity is used (i) as a reporter to directly
assess the interactions between the inserted peptides and the
target antibodies, and to easily monitor the enrichment of
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the phage library during the successive rounds of selection,
and (ii) as an agent of selection of phages expressing active
BHPs. Indeed, in order to amplify phages, phage-infected
cells are grown in a liquid medium in the presence of
ampicillin. Under these conditions, the bacterial growth is
directly associated with antibiotic resistance, and thus only
cells expressing active BlaP at the surface of phages are able
to grow [11].
This approach was first introduced by Legendre et al.,
who inserted random peptides within TEM-1, which was
displayed on phage fd in fusionwith the coat protein pIII [51].
The peptides were displayed on different loops surrounding
the active site of TEM-1: in one library, peptides replaced
residues A103 to 106; in a second library, they replaced
residues Thr271 and/or Met272, and these two libraries
were combined in a third one [51]. By selection from the
different libraries using three unrelated conformationalmon-
oclonal antibodies (mabs) recognizing distinct epitopes on
the prostate-specific antigen (PSA), several hybrid proteins
expressing small peptides with an affinity for these mabs in
the micro- and nanomolar range were isolated.The sequence
of these small peptides presents no similarity with that of
PSA, suggesting that mimotopes (i.e., peptides which bind
the antibody without having any identity to the antigen
sequence) were selected. These results indicate that BHPs
could effectively be used to display peptides at the surface of
phages.
An original epitope mapping strategy, inspired by the
work of Legendre et al., was developed by Bannister et al. and
Chevigne´ et al. [8, 11]. It involves constructing a phage display
library in which random fragments of different lengths of the
gene coding for the antigen of interest are exposed within
the 𝛽-lactamase BlaP (at position 197) in fusion with the
pIII protein at the surface of phages (Figure 3). A given
region of the target protein is displayed within peptides
of different lengths and could therefore adopt different
conformations. Sufficiently long peptides are likely to adopt
a fold similar to what they adopt in the full target protein [11].
As exemplified below, this technology allows the minimal
region of an antigen interacting with an antibody to be
identified with high accuracy (Figure 3) [11]. As the peptides
exposed within the 𝛽-lactamase are directly related to the
nucleotide sequence of the antigen, they do not correspond
to mimotopes. Moreover, the key amino acids within this
minimal region that are directly in contact with the antibody
can be further determined by point mutations as discussed
below (Figure 3) [8].
4.1. Mapping of Linear Epitopes. The BHP-implemented
phage display approach, developed by Chevigne´ et al. [11],
has allowed the determination of the linear epitope (i.e., an
epitope composed of amino acids that are in close proximity
in the sequence) of a high-affinitymonoclonal antibody (anti-
HAmab) specific to the virus influenza hemagglutinin (HA1).
Overlapping peptides of different sizes (from gene fragments
of 50 to 300 bp) of HA1were displayed on the solvent exposed
loop between 𝛼 helices 8 and 9 of BlaP, which was fused to
pIII coat protein of phages (Figure 3). The phages expressing
peptides containing the epitope region of HA1 were selected
by panning against anti-HA mab. After three rounds of
selection and amplification in the presence of ampicillin, a
series of phages expressing BHPs specific to anti-HAmabwas
selected. The sequencing of these phages shows a consensus
9-residues linear epitope of anti-HA mab (Figure 4). This
epitope is present in fragments of various sizes (from 13
to 70 residues) and can thus in principle adopt different
folds and solvent accessibilities. The gene coding for the
BHP displaying the consensus 9-residues epitope sequence
was cloned into the constitutive expression vector pNY. The
hybrid protein, referred to as BlaP-HA, was subsequently
expressed in the periplasm of E. coli and purified as a
bifunctional hybrid protein.The kinetic parameters (i.e.,𝐾
𝑚
,
𝑘cat, and 𝑘cat/𝐾𝑚) of BlaP-HA are similar to that of wild-
type BlaP, and it binds anti-HA mab with an affinity (𝐾
𝐷
) of
∼0.68 nM (Table 1) [11].
4.2.Mapping of Conformational Epitopes. A similar approach
was used by Bannister et al. to identify the conformational
epitope (i.e., epitope composed of amino acids located far
apart in the sequence but brought together by protein folding)
of the anti-CD22 immunotoxin CAT-8015 (mab 8015) [8].
CD22 (cluster of differentiation-22) is a cell surface glyco-
protein composed of a N-terminal Ig-like V-type domain
and various Ig-like C-type domains (Figure 5) [52–55]. This
protein is of particular therapeutic interest because it is a
specific marker present on the surface of malignant B-cells
and it is rapidly internalized upon binding; it constitutes
therefore a relevant target for an antibody drug conjugate
or immunotoxin approach. Despite the therapeutic interest
of CD22, very little is known concerning its structure or
that of the other related family members due to their high
level of glycosylation [8]. CAT-8015 is an immunotoxinwhich
combines a CD22-specific antibody variable fragment (Fv,
derived from the antibody mab 8015) with a Pseudomonas
exotoxin A (PE38); it exhibits a noteworthy clinical activity
in three leukaemia (i.e., chronic lymphocyte leukaemia, hairy
cell leukaemia, and acute lymphoblastic leukaemia) [8, 56,
57]. Antibody competition-binding studies have revealed that
the epitope of CAT-8015 is localized in the C-like domain 2
of CD22, but there is no information on its precise location
[8, 58].
In order to identify which residues of CD22 bind to CAT-
8015, Bannister et al. introduced random CD22 extracellular
domain gene fragments of 50 to 1000 bp into the permissive
exposed loop of BlaP (position 197) fused to the phage
pIII coat protein (Figure 3) [8]. A library containing 6 ×
105 transformants was obtained and screened against CAT-
8015 using the same strategy as that explained above. A
peptide-array analysis (Figure 3) confirmed that the entire
CD22 gene was well represented in the 𝛽-lactamase-positive
infectious phages, except two small regions of 7 residues
each. The minimal region of CD22 which binds to mab 8015
was identified. This region, referred to as CD22/C2C3, is
composed of 202 residues, from V234 to G435, located in the
C-terminal of the C-type domain 1, in the C-type domains
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2 and 3, and in the N-terminal of the C-type domain 4
(Figure 5).
The gene coding for the BHP displaying the minimal
region of CD22 was cloned into the constitutive expression
vector pNY. The hybrid BlaP-CD22/C2C3, produced as a
bifunctional hybrid protein in E. coli, conserves the 𝛽-
lactamase activity and binds to mab 8015 with a high affinity
(𝐾
𝐷
∼26.2 nM) (Table 1). To identify the key amino acids
involved in the antibody binding, an alanine-scanning muta-
genesis was performed (Figure 3) [11]. Thirty-four single-
point mutations to alanine were performed in three clusters
(referred to as clusters 1, 2, and 3) of CD22 encompassing
the epitope, and the resulting hybrid proteins were produced
and purified. Cluster 1 is located in the junction of C-type
domains 1 and 2, cluster 2 is located in C-type domain
3 and cluster 3 encompasses the junction between C-type
domain 3 and 4 and the N-terminal of C-type domain 4
(Figure 5). The binding of each mutant to mab 8015 was then
measured by enzyme-linked immunosorbent assay (ELISA)
and compared to that of the parent hybrid protein BlaP-
CD22/C2C3. This technique has allowed the identification
of the amino acids of high or intermediate importance in
the CD22-mab 8015 complex. The most important residues
encompass three discontinuous regions and they are mainly
located in C-type domains 2 and 3 (clusters 1 and 2), and few
are located in cluster 3. Modelling of different orientations of
these domains strongly suggests that they adopt a U-shaped
arrangement which allows the three clusters to be in close
enough proximity to form the epitope (Figure 5) [8].
These two examples show that alternating successive
affinity selections of phages and growth of phage-infected
cells in the presence of antibiotic permits the selection of
BHPs exhibiting both a high affinity for the target antigen and
an efficient enzymatic activity. They clearly demonstrate that
BHP technology using BlaP is a unique tool that allows the
identification of the antigen region involved in the antigen-
antibody interactions. It allows (i) the identification of linear
epitopes (i.e., the linear epitope of HA for anti-HA mab)
and (ii) the characterisation of complex epitopes (i.e., the U-
shaped discontinuous CD22 epitope of mab 8015). Moreover,
BlaP has enough conformational flexibility to allow inserted
antigen fragments of various lengths to fold and interact with
the antibody. BHPs allow therefore the identification of non-
linear epitopes (i.e., conformational epitopes) that are directly
linked to the nucleotide sequence of the antigen (i.e., not
a mimotope) [8, 11]. This approach can be further used to
identify the protein region involved in any protein-ligand
interactions.
4.3. BHPs as a Unique Tool for Immunoassay Develop-
ment. The 𝛽-lactamase implemented phage-display tech-
nique described above allows the selection of a particular
epitope as a bifunctional hybrid protein which associates the
epitope recognizing its specific target with an efficient enzy-
matic activity.This functionalization of the epitope allows the
rapid characterisation of the antigen-antibody interaction.
For example, the BlaP-HA hybrid protein was successfully
coated on solid surface to perform an ELISA, suggesting that
the solvent accessibility of the inserted polypeptide (i.e., the
epitope) was not altered when the hybrid protein is coated
[11]. Moreover, the enzymatic activity of BlaP can be used to
check the coating efficiency and to quantify the amount of
coated protein.
5. BHPs as Immunogenic Carriers for
Vaccine Development
Antibodies are specialized fighter proteins that are effective
in preventing infectious diseases. This property is based on
the recognition of specific epitopes on the surface of the
antigen that promotes the neutralization of the biological
activity of the antigen or the opsonisation of the pathological
agent. It is assumed that immunizationwith a precise epitope,
corresponding to an effective neutralizing antibody, would
elicit the generation of similarly potent antibodies in the
vaccine [38]. Thus, the insertion of these particular epitopes
into a carrier protein is often the starting point for the
development of a new generation of safe vaccines. Within the
carrier protein, the properties of the polypeptides, including
their antigenicity and immunogenicity, can be further modi-
fied [59]. In this context, the BHP technology, allowing the
insertion of a domain, subdomain, or a short polypeptide
from the native targeted antigen into a carrier 𝛽-lactamase,
is of particular interest to design such de novo antigens
(Figure 6). This approach is particularly relevant to antibody
raised against cryptic epitopes and non-immunodominant
antigens.
5.1. Generation of Vaccines against Poorly Immunogenic
Polypeptides/Proteins. TEM-1 hybrid proteins were created
in an attempt to develop a vaccine against the poorly antigenic
and non-immunogenic STa enterotoxin from enterotoxic E.
coli strains (ETEC). This toxin, which is associated with
enteric colibacillosis (characterized by severe diarrhoea) in
calves and piglets, leads to significant losses in agriculture
due to the death of newborns [60, 61]. STa is composed of 18
amino acids including 6 cysteins involved in three disulfide
bridges which are necessary for the toxic activity [62, 63]. STa
is poorly antigenic and is not immunogenic due to its small
size. No vaccine is yet available against this thermostable
toxin despite many attempts to design a safe vaccine (i.e.,
a non-toxic form of STa). The latter includes the chemical
coupling of the toxin to bovine serum albumin [64, 65],
to the 𝛽-subunit of cholera toxin [66], and to the heat-
labile enterotoxin (LT) [65, 67], and its fusion to the major
protein subunit ClpG of E. coli CS31A surface antigen [68],
to several subunits of cholera toxin [66, 69], to LT [70, 71], to
OmpC [70], and to flagellin [72]. These constructions either
failed to induce the production of neutralizing antibodies
against STa or retained a certain degree of toxicity. However,
Wu and Chung have managed to elicit the production of
protective antibodies against the antigen STLT (i.e., a fusion
of the thermostable ST and thermolabile LT enterotoxins) in
mice using a protein fusion between GFP and STLT. These
immunized mice presented a subsequent full protection
against ETEC [73].
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Cl 1   FVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTEV
Cl 2     VERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTEVTQNGGS
Cl 3     VERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTEVTQNGGS
Cl 4     VERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTEV
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Cl 11                      NCYPYDVPDYASLRSL
 Consensus               CYPYDVPDYASL
Figure 4: Consensus sequence recognized by anti-HA mab. Multiple sequence alignment from eleven individual clones selected after three
rounds of selection of phages on anti-HA mab. The residues corresponding to the epitope recognized by the anti-HA mab are underlined.































Figure 5: Schematic representations of the glycoprotein CD22 in a linear and U-shaped arrangement. In the linear arrangement, the three
clusters forming the epitope are far away from each other whereas they are close in a U-shaped arrangement [8]. The residues involved in
the complex with mab 8015 are clustered in cluster 1, 2, and 3 and are shown in light blue, red, and green, respectively. Figure adapted from
Bannister et al. [8].
Different approaches based on the use of TEM-1 hybrid
proteins have been used in order to design a vaccine against
STa [9, 14, 15]. First, Ruth et al. have designed DNA vacci-
nation to induce the production of neutralizing antibodies
against STa [14]. STa and three variant forms, in which
one (STaC6A, STaC17A) or two (STaC6A-C17A) of the six
cysteines have been mutated (in order to disrupt one or
two disulphide bridges and cause a complete loss of the
toxicity of the toxin), have been inserted either in position
195 (loop A) or 216 (loop B) of TEM-1. Plasmid DNA
encoding these hybrid proteins has been used to immunize
mice. Following immunizations, different levels of anti TEM-
1 antibodies were generated.The level of antibody production
against TEM-1 was higher for mice immunized with plasmid
DNA coding for BHPs displaying STa and its variants in
position 216 (loop B) than in position 195 (loop A). Since
insertions in loop B interfere less with anti TEM-1 antibody
production than insertion in loop A, this suggests that the
immunodominant epitope of TEM-1 is located in the region
of loop A. In contrast, no antibody specific to STa could be
detected, even after 3 injections of the different plasmids.
Two subsequent boosts with a STa toxin obtained by peptide
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synthesis, which is not immunogenic, did however induce
the production of STa-specific antibodies in mice initially
primed with plasmids encoding hybrid proteins, but not
when primed with plasmid encoding TEM-1. This clearly
indicates that hybrid proteins were expressed in mice and
have primed the production of antibodies specific to STa.The
ability of sera containing STa specific antibodies to neutralize
the toxin was determined by suckling mouse assays. Only
the sera from mice immunized with the plasmid coding
for the double disulfide bridge mutated variant (STaC6A-
C17A) and boosted with STa injections show neutralizing
activity. These results indicate that the use of the toxic form
of STa is therefore not needed to induce the production
of neutralizing antibodies. These results also indicate that
TEM-1 is an appropriate carrier to present nonimmunogenic
peptide to the immune system. Indeed, the carrier is required
for the induction of helper T cells allowing the production
of antibodies against the carrier, TEM-1, and the hapten,
STa. Moreover, the best location for the insertion seems to
be located at position 195, the immunodominant epitope of
TEM-1. Indeed, exposing the insert at this position reduces
the production of anti TEM-1 antibodies and should therefore
decrease the competition between the hapten and the carrier
for the B-cell immune response [14].
Subsequently, recombinant hybrid TEM-1 proteins in
which STa has been inserted at different positions, including
positions 195 and 216, were designed, produced, and used for
mice immunization (Figure 6) [9]. This study revealed that
the hybrid proteins elicit the production of antibodies mainly
against TEM-1, and in much lower quantity against STa.
TEM-1 with the insertion at position 195 induces the highest
production of anti-STa antibody and most importantly was
the only hybrid protein that leads to the production of
antibodies neutralizing the toxicity of STa. These results
are in good agreement with results obtained with DNA
vaccination and confirm that B-cell epitopes of the carrier
are immunodominant. Moreover, the carrier, TEM-1, con-
tains the functional helper T cell epitopes necessary for the
immune response against the hapten, STa [9].
Following these encouraging results, Zervosen et al.
immunized cattle with a TEM-1 hybrid protein containing
the STa in position 197 in the presence of 3 different adjuvants
(Table 1) (Montanide ISA70 - ISA206 and IMS1313) [15]. High
levels of different IgG types specific to TEM-1 were detected,
and in vitro neutralization of the 𝛽-lactamase activity was
observed by mixing purified TEM-1 with sera. In contrast,
specific anti-STa IgG and IgG1 antibodies were only detected
at non-significant levels, and no IgG2 were detected in the
sera of the immunized cattle. These results suggest that the
response of the bovine immune system is different from that
observed inmice [9, 15].The use of a series of other adjuvants
to immunize cattle needs to be investigated.
5.2. Production of Neutralizing Antibodies against Difficult-to-
Express Antigens. As discussed above, BlaP can be used as a
scaffold to produce and to purify the chitin binding domain
from chitotriosidase (ChBD) [13]. The purified ChBD has
been used to immunize a rabbit (Figure 6). The resulting
serum contains antibodies that are able to bind to the
free ChBD, the hybrid BlaP-Thb/ChBD/Thb, and the native
human macrophage chitotriosidase. Moreover, these anti-
ChBD antibodies are able to prevent the interaction of ChBD
with chitin [13].
Taken all together, the results of these studies indicate that
both BlaP and TEM-1 are appropriate scaffolds for producing
and presenting antigens and inducing the production of
antibodies neutralizing biological properties of the inserted
fragment (Figure 6).
6. BHPs as Model Proteins to Investigate
Structure/Function Relationships
6.1. BlaP: A Scaffold to Create Protein Models to Study the
MechanismofAmyloid Fibril Formation by Polyglutamine Pro-
teins. Ten progressive neurodegenerative disorders, referred
to as polyglutamine (polyQ) diseases, and, including Hunt-
ington’s disease and several spinocerebellar ataxias, are asso-
ciated with ten unrelated proteins containing an expanded
polyglutamine (polyQ) tract (i.e., a tract that is longer than
a pathological polyglutamine threshold). PolyQ tracts are
encoded by a repetition of an unstable CAG trinucleotide
repeat in the corresponding genes [74–77]. The ten disease-
associated proteins show no sequence or structural similarity
apart from the expanded polyQ tract, which is located at a
different positions in each protein. The polyQ tract appears
therefore to be a critical determinant in polyQ diseases, and
several lines of evidence suggest that it confers a gain of toxic
function to the mutant proteins by triggering the aggregation
of the proteins into amyloid fibrils [74, 75, 78–80]. Indeed, all
polyQ diseases share a number of features which suggest a
common physiopathological mechanism [75, 79–81]: (i) the
existence of a polyQ threshold for the aggregation of polyQ
proteins and the disease development, generally comprised
between 35 and 45Q [82], (ii) the so-called anticipation
phenomenon, which indicates that the longer the polyQ,
the earlier and more severe the disease [76, 83–85], and
(iii) the presence of intranuclear inclusion bodies, containing
amyloid fibrils made of polyQ proteins, in neuronal cells
[75, 76, 85, 86].
So far, there is no preventive or curative treatment for
these pathologies and existing therapies only treat the symp-
toms (i.e., they alleviate the symptoms without modifying
the course of the disease). In order to design curative and/or
preventive treatments, it is crucial to better understand
how polyQ tracts trigger protein aggregation and by which
mechanism some of the aggregates formed are cytotoxic.
Although the presence of the expanded polyQ tract is
the critical trigger factor of the aggregation phenomenon,
a growing number of studies suggest that the non-polyQ
regions can, however, modulate both the kinetics and the
aggregation pathway of polyQ proteins [74, 78, 87–90]. The
non-polyQ regions can protect from aggregation by (i) ster-
ically hindering polyQ intermolecular interactions [91], (ii)
restricting polyQ conformational changes which are required
for fibril formation [89] and (iii) increasing the protein
solubility [87, 91]. On the other hand, non-polyQ regions
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Figure 6: Schematic representation of the BHP technology used to design de novo antigens in order to induce the production of neutralizing
antibodies. A specific region of a large antigen, that is known to promote the neutralization of the biological activity of the antigen or promote
its opsonization, is inserted into BlaP. This approach can also be used to elicit the production of specific, neutralizing antibodies against
polypeptides that are insoluble, difficult to express (i.e., ChBD, [13]), and poorly immunogenic (such as STa, [9]).
could assist aggregation by providing additional aggregation-
prone domains [74, 92]. There is, therefore, a complex
interplay between the tendency of the polyQ tract to trigger
aggregation and the modulating effect of non-polyQ regions
[16]. To better understand the general principles governing
this complex phenomenon, it is crucial to investigate in
detail which properties of the host protein (sequence, size,
structure, and stability) influence the ability of polyQ tracts
to mediate aggregation. The ten disease-associated proteins
are difficult to produce recombinantly due to their large
size and/or relative insolubility [74, 92–94]. Scarafone et al.
tackled this problem by creating and characterizing model
polyQ proteins consisting of the 𝛽-lactamase BlaP and polyQ
tracts inserted at position 197 [16]. Significant amounts (i.e.,
10–20mg per liter of culture) of hybrid enzymes containing
23, 30, 55, and 79Qwere successfully produced andpurified. It
is important to note that the longest polyQ tract that has been
inserted in other model proteins is made of 55 residues [95].
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Figure 7: Model polyQ proteins using BlaP to investigate the amyloid fibril formation. The advantage of using BlaP as a scaffold to create
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. Under native conditions, the threshold value is therefore comprised
between 55 and 79Q. Under denaturing conditions, it is comprised between 30 and 55Q. Moreover, the kinetics of aggregation are faster with








. N, native state; U, unfolded
state; F, amyloid fibril.The native conformation of BlaP imposes constraints to the 55Q tract that prevent it to trigger the formation of amyloid
fibrils. Figure adapted from Scarafone et al. [16].
BlaP is therefore a unique scaffold to investigate the effects of
long inserted polyQ sequences (Figure 7).
The effects of the polyQ insertions on the activity, struc-
ture, and aggregation of BlaP were investigated using a range
of biophysical techniques. The activity and the secondary
and tertiary structures of BlaP are essentially not affected
by the insertion of the polyQ tract as long as 79Q. The
polyQ tract adopts a disordered structure at the surface of
the protein irrespective of the number of glutamines. BlaP
is significantly destabilized, however, by the insertion of
the polyQ tract. Remarkably, the extent of destabilization is
largely independent of the polyQ length (7.6–8.8 kJ⋅mol−1;
Table 1). This behaviour therefore makes it possible to
investigate independently the role of (i) the length of the
polyQ sequence and (ii) the conformational state of the 𝛽-
lactamase moiety on the aggregating properties of the hybrid
proteins. Accordingly, the aggregating properties of BlaP and
of the different hybrid proteins were investigated under both
native and denaturing conditions.The aggregation behaviour
of BlaP-polyQ hybrid proteins recapitulates that of disease-
associated polyQ proteins. Only hybrid proteins with 55Q
and 79Q readily form amyloid fibrils; therefore, analogous to
the proteins associated with diseases, there is a polyglutamine
threshold required for the formation of amyloid fibrils.
Moreover, above this threshold, the longer the polyQ, the
faster the aggregation rate (Figure 7). Most importantly, the
threshold-value critically depends on the structural integrity
of BlaP. BlaP with 55Q forms fibrils under denaturing but not
under native conditions (Figure 7).Thismeans that the native
conformation of BlaP imposes some conformational and/or
steric constraints to the 55Q tract that inhibit fibril formation.
On the other hand, the hybrid protein containing 79Q forms
amyloid fibrils at similar rates whether BlaP is folded or not
(Figure 7). These results therefore suggest that the influence
of the protein context on the aggregation properties of polyQ
disease-associated proteins could be negligible when the
latter contain particularly long polyQ tracts [16].
Taken all together, these results indicate that BlaP is an
appropriate host to study the aggregation of polyQ proteins.
Its utility could be extended to the study of how other
amyloidogenic peptides trigger protein aggregation.
6.2. Effect of the Structure of the Insert on BHP Stabilities.
Vandevenne et al. [10] extensively investigated the effects of
the insertion of the ChBD domain on the thermodynamic
stability of BlaP, as indicated above. They observed that
the insertion of this 72-residue folded domain at position
197 slightly destabilizes BlaP by 3.2 kJ⋅mol−1 (Table 1) [10].
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This destabilization is significantly lower than that induced
by the insertion of unstructured polyQ tracts of 23 to 79
residues, inserted into the same position (7.6–8.8 kJ⋅mol−1,
Table 1) [16]. This observation suggests that the insertion
of unstructured polypeptides is more destabilizing than the
insertion of folded polypeptides.
6.3. BHPs as Models to Screen Molecules Stabilizing Polypep-
tides. A growing number of peptide and protein drugs
are utilized in therapy [96]. Unfortunately, because of
unfavourable solubility, stability, and aggregation, their appli-
cations are sometimes difficult [96]. To circumvent this prob-
lem, low molecular weight additives, called cosolutes, have
been developed, including cyclodextrins [96, 97]. Cyclodex-
trins are circular oligosaccharides containing a central cavity
forming the resting site for hydrophobic molecules of an
appropriate dimension [98]. They are generally used to
prevent protein aggregation during the renaturation process
[12, 96]. BCD07056 is a modified 𝛽-cyclodextrin, one of the
most abundant classes of cyclodextrin [96].
Vandevenne et al. used the hybrid protein BlaP-ChBD,
incubated under drastic conditions, to investigate the effects
of BCD07056 on the stability of proteins [12]. They observed
that BCD07056 does not affect the chitin binding of BlaP-
ChBD, yet increases its 𝛽-lactamase activity. More inter-
estingly, this 𝛽-cyclodextrin minimizes the inactivation of
BlaP-ChBD upon storage at room temperature; its addition
cannot, however, reverse the inactivation process. The 𝛽-
cyclodextrin has a moderate effect on the thermal stability
of BlaP-ChBD. However, its presence restores a cooperative
reversible thermal unfolding, with a simple two-state tran-
sition, characteristic of BlaP without insert. This suggests
that BCD07056 prevents the aggregation of BlaP-ChBD by
interacting with the protein during the unfolding process.
BCD07056 is therefore an effective additive to stabilize
proteins during their storage and prevent their aggregation,
without interfering with their activity [12]. It could be used to
facilitate the application of a growing number of peptide and
protein drugs in therapy [96].
7. Conclusion
Class A 𝛽-lactamase hybrid proteins, in which exoge-
nous polypeptides of various sizes are inserted (up to
40 kDa), can be readily designed and used for multi-
ple purposes, notably to produce difficult-to-express pep-
tides/proteins/protein fragments, to map epitopes, to dis-
play antigens, and to study protein structure/function rela-
tionships. The wide ranging impact of the BHP approach
essentially originates from (i) the efficient enzymatic activity
that can be easily measured and that can serve as a reporter
or factor for selection and (ii) the facility with which they
can be recombinantly produced and purified. In addition to
the numerous applications summarized in this review, many
other applications can be envisaged: BHPs could be used as
biosensors and in affinity chromatography, drug screening,
and drug targeting. They are also of special interest to better




BHPs: 𝛽-lactamase hybrid proteins
BlaP: 𝛽-lactamase from Bacillus licheniformis 749/C
CD22: Cluster of differentiation-22
ChBD: Chitin binding domain
dsbA: Disulfide bond isomerase A
ELISA: Enzyme-linked immunosorbent assay
ETEC: Enterotoxic E. coli
GFP: Green fluorescent protein





NMR: Nuclear magnetic resonance
polyQ: Polyglutamine
PSA: Prostate specific antigen
Thb: thrombin.
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